In a groundbreaking development, researchers from the Technical University of Denmark have unveiled an AI platform that can customize protein components to empower a patient’s immune cells to combat cancer. This innovative method marks a significant advancement in precision personalized cancer treatment, showcasing the ability to computer-design binder molecules that direct the patient’s immune cells to engage with the pMHC molecules of cancer cells.
By drastically reducing the timeline for identifying effective molecules for cancer therapy from years to just a few weeks, this AI platform is revolutionizing the landscape of cancer treatment. Led by DTU associate professor Timothy P. Jenkins, the platform has the capacity to rapidly design molecular structures against cancer cells, offering the potential for new and promising molecules within a mere 4-6 weeks. Developed in collaboration with Scripps Research, this AI platform not only enables targeted treatments against tumor cells but also presents a solution to the challenge of minimizing damage to healthy tissue, a critical aspect of cancer immunotherapy.
Read more from biotechniques.com